Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY) Short Interest Up 32.2% in August

Key Points

• Short interest in Daiichi Sankyo has increased by 32.2%, reaching a total of 101,000 shares as of August 31, up from 76,400 shares on August 15.
• The company's stock currently has a market capitalization of $45.57 billion and trades at approximately $24.06 per share.
• Nomura Securities has upgraded Daiichi Sankyo to a "strong-buy" rating, contributing to an average rating of "Strong Buy" among analysts.

Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) saw a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 101,000 shares, a growth of 32.2% from the August 15th total of 76,400 shares. Approximately 0.0% of the company's shares are short sold. Based on an average daily volume of 611,300 shares, the short-interest ratio is presently 0.2 days. Based on an average daily volume of 611,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the company's shares are short sold.

Wall Street Analyst Weigh In

Separately, Nomura Securities raised Daiichi Sankyo to a "strong-buy" rating in a research note on Friday, June 6th. One equities research analyst has rated the stock with a Strong Buy rating, According to MarketBeat, the company presently has a consensus rating of "Strong Buy".

Daiichi Sankyo Price Performance

Shares of OTCMKTS DSNKY traded down $0.73 during mid-day trading on Friday, hitting $23.96. 102,441 shares of the stock traded hands, compared to its average volume of 187,032. The company has a market cap of $45.39 billion and a PE ratio of 23.26. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.85. Daiichi Sankyo has a twelve month low of $20.92 and a twelve month high of $35.10. The firm has a 50 day simple moving average of $24.47 and a two-hundred day simple moving average of $24.21.

Daiichi Sankyo Company Profile

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.